MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin - Full Text View

MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin (MacTEL-Supp)

This study is currently recruiting participants.

Verified by The Lowy Medical Research Institute Limited, December 2007

First Received: December 5, 2007 No Changes Posted

Sponsors and Collaborators:	The Lowy Medical Research Institute Limited None
Information provided by:	The Lowy Medical Research Institute Limited
ClinicalTrials.gov Identifier:	NCT00568828

Purpose

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

investigate Lutein and Zeaxanthin serum levels in MACTEL probands
investigate and quantify MP at the posterior pole of MACTEL probands
detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

Condition
Macular Teleangiectasia Macular Pigment

MedlinePlus related topics: Dietary Supplements

Drug Information available for: Lutein Zeaxanthin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

Further study details as provided by The Lowy Medical Research Institute Limited:

Primary Outcome Measures:

Macular Pigment Optical Density [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	12
Study Start Date:	December 2007
Estimated Study Completion Date:	February 2008

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

12 patients with Macular Teleangiectasia

Criteria

Inclusion Criteria:

Different distribution of macular pigment in patients with known macular teleangiectasia

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568828

Contacts

Contact: Daniel Pauleikhoff, MD

49-251-933080

dapauleikhoff@muenster.de

Locations

Germany
Dep. of Ophthalmology, St. Franziskus Hospital	Recruiting
Muenster, Germany, 48145
Contact: Meike Zeimer, MD 49-251-933080 kpl-auge@muenster.de

Sponsors and Collaborators

The Lowy Medical Research Institute Limited

None

Investigators

Principal Investigator:

Daniel Pauleikhoff, MD

Chairman Dep. of Ophthalmology, St.Franziskus Hospital, Muenster, Germany

More Information

No publications provided

Responsible Party:	Dep. of Ophthalmology, St. Franziskus Hospital, Muenster, Germany ( Daniel Pauleikhoff MD )
Study ID Numbers:	MacTEL Supplement, no
Study First Received:	December 5, 2007
Last Updated:	December 5, 2007
ClinicalTrials.gov Identifier:	NCT00568828 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by The Lowy Medical Research Institute Limited:

Macular Teleangiectasia
Macular Pigment

ClinicalTrials.gov processed this record on May 06, 2009